Beranda › Limfoma Sel-T
Uji klinis Limfoma Sel-T yang merekrut di AS
35 studi untuk Limfoma Sel-T merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- New York City, NY13 studi
- Philadelphia, PA10 studi
- Baldwin Park, CA9 studi
- Boston, MA9 studi
- Houston, TX8 studi
- Atlanta, GA8 studi
- Chicago, IL6 studi
- Seattle, WA6 studi
- Columbus, OH6 studi
- Rochester, MN6 studi
- Miami, FL5 studi
- New Haven, CT5 studi
- Ann Arbor, MI4 studi
- Scottsdale, AZ4 studi
- Portland, OR4 studi
- Cedar Rapids, IA4 studi
- Baltimore, MD4 studi
- Durham, NC4 studi
- St. Louis, MO4 studi
- Charlottesville, VA4 studi
- Aurora, CO3 studi
- Los Angeles, CA3 studi
- San Diego, CA3 studi
- Charlotte, NC3 studi
- San Francisco, CA3 studi
- Madison, WI3 studi
- Edison, NJ3 studi
- Staten Island, NY3 studi
- Queens, NY3 studi
- Omaha, NE3 studi
- New Rochelle, NY3 studi
- Rochester, NY3 studi
- Salt Lake City, UT3 studi
- East Norwalk, CT3 studi
- Cincinnati, OH3 studi
- Indianapolis, IN3 studi
- Milwaukee, WI3 studi
- Tampa, FL3 studi
- Minneapolis, MN3 studi
- Denver, CO3 studi
Berdasarkan negara bagian
- Arizona5 studi
- California13 studi
- Colorado6 studi
- Connecticut5 studi
- Florida8 studi
- Georgia8 studi
- Illinois7 studi
- Indiana3 studi
- Iowa4 studi
- Maryland4 studi
- Massachusetts9 studi
- Michigan5 studi
- Minnesota9 studi
- Missouri4 studi
- Nebraska3 studi
- New Jersey4 studi
- New York15 studi
- North Carolina6 studi
- Ohio8 studi
- Oklahoma3 studi
- Oregon4 studi
- Pennsylvania12 studi
- Texas9 studi
- Utah3 studi
- Virginia5 studi
- Washington6 studi
- Wisconsin5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04803201Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06724237A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06854653A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04104776Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07382817Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06390319CD45BE-HSPC + CART-45 Cells
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07451054Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07750886Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT03011814Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Menerima pesertaFase 1
Usia 0 hingga 29 · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06934382Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT03501576Allo HSCT Using RIC and PTCy for Hematological Diseases
Menerima pesertaFase 2
Hingga usia 75 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT05805605Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT06508463CD4CAR for CD4+ Leukemia and Lymphoma
Menerima pesertaFase 1
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT03829540A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT05463263Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT03017820Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2026 · NCT07278856A Registry for People With T-cell Lymphoma
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT05978141Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mei 2026 · NCT07225985Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.